Liquid Biopsy for Cancer Detection

Liquid biopsy detects fragments of cancer DNA called ctDNA released by tumor cells into the bloodstream through a simple blood draw without putting a needle into the tumor. It identifies tumor mutations for drug selection, monitors treatment response in real time, and catches recurrence months before scans show anything visible. The technology is still evolving but FDA-approved ctDNA tests already exist for lung, breast, and colorectal cancers.

According to Dr. Sandeep Nayak, Best cancer treatment in Bangalore, “Patient finishes chemo and wants to know if it worked. Earlier we waited three months for a CT. Now a blood test tells us whether tumor DNA is still circulating or not. Blood goes clean means cancer responded. Blood stays positive means we know before the scan does.”

Not a replacement for tissue biopsy. A companion that answers questions tissue can’t address without another surgical procedure.

• Find mutations from blood: EGFR, ALK, BRAF mutations identified from a blood sample when the tumor is inaccessible or risky to biopsy. Lung cancer sitting next to major vessels gets its molecular profile from blood instead of a needle through the chest wall.
• Monitor treatment: ctDNA drops when treatment works and rises when cancer progresses. Oncologist sees this weeks before CT shows size change. Like checking engine temperature instead of waiting for smoke from the bonnet.
• Detect recurrence early: Minimal residual disease testing picks up cancer DNA in blood when scans look completely clean. ctDNA turning positive predicts recurrence 6-12 months before imaging confirms it. Early warning that gives time to act.
• Track resistance: Cancer evolving drug resistance shows new mutations in circulating DNA. Oncologist switches treatment based on blood results instead of waiting for the tumor to grow then biopsying it again to find out why.

Your oncologist integrates liquid biopsy into precision oncology alongside imaging and tissue analysis.

Powerful but not perfect. Knowing where it falls short prevents spending money on technology that sounds impressive but doesn’t change the plan.

• Not for initial diagnosis: Tissue biopsy remains gold standard for confirming cancer. Early-stage tumors shed too little DNA into blood for reliable detection. Negative liquid biopsy doesn’t mean no cancer. Means the test didn’t find enough fragments to call it.
• False positives: Inflammation, autoimmune conditions, and clonal hematopoiesis in older patients produce abnormal DNA signals mimicking cancer. Getting tested without clinical context creates unnecessary panic and follow-up procedures costing lakhs.
• Cost in India: 20,000-80,000 rupees depending on panel and lab. Most insurance doesn’t cover it yet. Ordering it when clinical benefit isn’t clear is spending money on a test that sounds modern but doesn’t change what happens next.
• Varies by cancer: Works well for lung, colorectal, breast where ctDNA shedding is higher. Less reliable for brain tumors where the blood-brain barrier blocks DNA release and for very early cancers where tumor burden is too small to detect.

Understanding how sentinel biopsy provides tissue answers imaging can’t replicate explains why liquid biopsy follows the same principle of accessing molecular information through smarter less invasive sampling.

Dr. Sandeep Nayak’s team at MACS Clinic uses liquid biopsy selectively where it changes clinical decisions including mutation profiling for inaccessible tumors, treatment monitoring, and minimal residual disease detection after curative surgery.

Blood test here has a specific clinical question attached. Not ordered because the technology is trending or the patient read about it online. Test without a purpose is data without direction.

Call +91 8035740000 to book your consultation.

References

1. Liquid biopsy in oncology — National Cancer Institute
2. Circulating tumor DNA detection — World Health Organization